Skip to content
Catalyst

knowcompoundsCyanocobalamin (vitamin B12)findings

Every finding on cyanocobalamin (vitamin B12)

14 findings, by evidence strength

Direction
Strength, at least

14 shown

  1. Alanine aminotransferaseMoved: no difference foundEvidence: ModeratePaper: PMID 359821622022Industry funded
    Who
    Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
    Dose studied
    1000 µg cyanocobalamin, one oral tablet daily for 12 weeks

    Although serum levels of ALT in the vitamin B12 group decreased significantly, this change did not reach a significant level compared to the placebo group.”

    Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.RCT · 3 monthsPermalink
  2. Fasting blood glucoseMoved: no difference foundEvidence: ModeratePaper: PMID 359821622022Industry funded
    Who
    Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
    Dose studied
    1000 µg cyanocobalamin, one oral tablet daily for 12 weeks

    In the vitamin B12 group, the levels of FBG significantly decreased; however, the between-group comparison revealed a nonsignificant P-value (P = 0.167).”

    Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.RCT · 3 monthsPermalink
  3. Malondialdehyde (circulating)Moved: no difference foundEvidence: ModeratePaper: PMID 359821622022Industry funded
    Who
    Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
    Dose studied
    1000 µg cyanocobalamin, one oral tablet daily for 12 weeks

    The serum levels of MDA were reduced significantly in the vitamin B12 group; however, this change was not significant compared to the placebo group (Table 4).”

    Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.RCT · 3 monthsPermalink
  4. Prostate cancer incidenceMoved: raisesEvidence: ModeratePaper: PMID 205017712010
    Who
    Men in a nested case-control study (ProtecT, 1,461 cases and 1,507 controls) pooled with published studies; exposure is circulating B12 concentration
    Dose studied
    not reported

    Vitamin B(12) and (in cohort studies) folate were associated with increased prostate cancer risk.”

    Quoted verbatim from Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis.meta-analysisPermalink
  5. Plasma total homocysteine (tHcy) concentrationMoved: lowersEvidence: Moderatereplicated ×1Paper: PMID 202165602010Industry funded
    Who
    Indian children (mean age 9 y) and their parents from 119 rural families of the Pune Maternal Nutrition Study; B12 arms (B2, B10) compared with the no-B12 arm (B0), with folic acid 0 or 200 μg distributed across all B12 arms (factorial design, arms pooled over folic acid); 12 months, tHcy by fluorescence polarization immunoassay on fasting plasma
    Dose studied
    vitamin B12 2 μg or 10 μg capsule orally daily before breakfast, for 12 months

    Plasma tHcy concentrations fell in the B2 and B10 groups, and showed little change in the B0 group.”

    Quoted verbatim from Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India.RCT · 12 monthsPermalink
  6. Lung cancer incidenceMoved: raisesEffect, as reportedOR1.15[1.06 to 1.25]Evidence: LimitedPaper: PMID 304991352019
    Who
    5183 lung cancer cases and matched controls nested within 20 prospective cohorts (Lung Cancer Cohort Consortium); pre-diagnostic circulating vitamin B12, per doubling, overall lung cancer
    Dose studied
    not reported

    Directly measured circulating vitamin B12 was positively associated with overall lung cancer risk in the LC3 consortium (OR for a doubling in vitamin B12 [ORlog2B12] = 1.15, 95% confidence interval [95%CI] = 1.06-1.25, Figure 1).”

    Quoted verbatim from Is high vitamin B12 status a cause of lung cancer?case-controlPermalink
  7. Serum vitamin B12 (cobalamin) concentrationMoved: raisesEffect, as reportedMD68.53[41.83 to 95.23]Evidence: Very limitedreplicated ×1Paper: PMID 422273072026
    Who
    Children under 12 years in randomised trials of oral vitamin B12 alone versus placebo, pooled · n = 705
    Dose studied
    not reported

    Vitamin B12 supplementation in children reduces vitamin B12 deficiency (absolute risk difference (ARD) 56 fewer per 1000, 95% CI 68 fewer to 24 fewer; 1.8% versus 7.6%; risk ratio (RR) 0.27, 95% CI 0.11 to 0.69; 3 trials, 642 children; high-certainty evidence), and probably increases total vitamin B12 concentrations (MD 68.53 pmol/L, 95% CI 41.83 to 95.23; 7 trials, 705 children; moderate-certainty evidence), compared to placebo, with an average increase of 68.5 pmol/L.”

    Quoted verbatim from Vitamin B12 supplementation for growth, development, and cognition in children.meta-analysisPermalink
  8. Serum vitamin B12 (cobalamin) concentrationMoved: raisesEvidence: Very limitedreplicated ×1Paper: PMID 245988852014
    Who
    Pregnant women under 14 weeks of gestation in Bangalore, India, all given iron and folic acid throughout pregnancy in both arms; plasma B12 at the second and third trimesters
    Dose studied
    vitamin B-12 50 μg orally daily from before 14 weeks of gestation through 6 weeks postpartum

    Compared with placebo recipients, vitamin B-12-supplemented women had significantly higher plasma vitamin B-12 concentrations at both the second (median vitamin B-12 concentration: 216 vs. 111 pmol/L, P < 0.001) and third (median: 184 vs. 105 pmol/L, P < 0.001) trimesters.”

    Quoted verbatim from Vitamin B-12 supplementation during pregnancy and early lactation increases maternal, breast milk, and infant measures of vitamin B-12 status.RCTPermalink
  9. All-cause mortalitycontestedMoved: raisesEffect, as reportedHR1.5[1.29 to 1.74]Evidence: Very limitedPaper: PMID 382527872024
    Who
    Pooled cohort studies of adults; high circulating serum vitamin B12 category (>600 pmol/L) versus the reference category; no one was dosed
    Dose studied
    not reported

    The meta-analysis of cohort studies showed a positive association between a high serum vitamin B12 concentration (>600 pmol/L) and all-cause mortality (adjusted HR 1.50, 95 % CI 1.29 to 1.74; n = 10; p < 0.01), CVD mortality (adjusted HR 2.04, 95 % CI 0.99 to 4.19; n = 2; p = 0.02), except cancer mortality (adjusted HR 1.56, 95 % CI 0.82 to 2.95; n = 3).”

    Quoted verbatim from The origin of vitamin B12 levels and risk of all-cause, cardiovascular and cancer specific mortality: A systematic review and dose-response meta-analysis.meta-analysisPermalink
  10. Health-related quality of lifeMoved: raisesEvidence: Very limitedPaper: PMID 304778532018
    Who
    Patients with postherpetic neuralgia; pooled randomised trials of vitamin B12 against placebo
    Dose studied
    not reported

    Vitamin B12 administration improved the quality of life of PHN patients with moderate quality evidence and significantly decreased the number of patients using analgesics.”

    Quoted verbatim from Vitamin B12 for herpetic neuralgia: A meta-analysis of randomised controlled trials.meta-analysisPermalink
  11. Numeric rating scale (NRS) pain intensityMoved: lowersEffect, as reportedMD−4.01[−4.7 to −3.33]Evidence: Very limitedPaper: PMID 304778532018
    Who
    Patients with postherpetic neuralgia; pooled randomised trials of vitamin B12 against placebo
    Dose studied
    not reported

    Compared with the placebo group, the Vitamin B12 group exhibited a significant decrease in the Numeric Rating Scale score, with a mean difference of -4.01 (95% confidence interval = -4.70 to -3.33).”

    Quoted verbatim from Vitamin B12 for herpetic neuralgia: A meta-analysis of randomised controlled trials.meta-analysisPermalink
  12. All-cause mortalitycontestedMoved: no difference foundEffect, as reportedHR0.74[0.49 to 1.11]Evidence: Very limitedPaper: PMID 332980542020Industry funded
    Who
    1533 community-dwelling Dutch adults aged 60-75 years in the Lifelines-MINUTHE subcohort; baseline serum vitamin B12 (per doubling) against all-cause mortality over a median 5.3 years; univariable Cox analysis · n = 1,533
    Dose studied
    not reported

    In univariable Cox regression analyses, we found a significant association of log2 MMA with mortality (HR 1.67 (95% CI 1.25–2.22), P < 0.001) and eGFR (per 10 mL/min/1.73 m2) with mortality (0.73 (0.62–0.85), P < 0.001), while log2 vitamin B12 was not significantly associated with mortality (0.74 (0.49–1.11), P = 0.1).”

    Quoted verbatim from Methylmalonic acid, vitamin B12, renal function, and risk of all-cause mortality in the general population: results from the prospective Lifelines-MINUTHE study.cohortPermalink
  13. Total sleep timeMoved: no difference foundEvidence: Very limitedPaper: PMID 349993242022
    Who
    Infants aged 6-11 months at risk of vitamin B12 deficiency (length-for-age below one z-score) in low-to-middle-income neighbourhoods of Bhaktapur, Nepal; total sleep duration (day and night) measured by actigraphy
    Dose studied
    daily vitamin B12 supplementation for one year versus placebo

    There was no effect of vitamin B12 supplementation on sleep duration at night, total sleep duration, or WASO.”

    Quoted verbatim from The effect of vitamin B12-supplementation on actigraphy measured sleep pattern; a randomized control trial.RCT · 12 monthsPermalink
  14. Plasma total homocysteine (tHcy) concentrationMoved: lowersEffect, as reportedMD−4.15[−4.86 to −3.45]Evidence: Very limitedreplicated ×1Paper: PMID 374952102024
    Who
    Participants in 21 randomized controlled trials of B12 supplementation as an isolated supplement; pooled across B12 forms, doses and durations
    Dose studied
    not reported

    Hcy levels were significantly lower after B12 supplementation compared with the control group (pooled weighted mean difference, -4.15 μmol/L; 95% confidence interval, -4.86, -3.45; P < 0.001), and this reduction was even greater with intervention durations ≥12 weeks and doses >500 µg/d.”

    Quoted verbatim from A comprehensive review and meta-regression analysis of randomized controlled trials examining the impact of vitamin B12 supplementation on homocysteine levels.meta-analysisPermalink

No dose is advised.